Extracted from this filing and checked against the source text.
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
VSEE HEALTH, INC. amended First Amendment to Second Amended and Restated Business Combination Agreement (the "First Amendment") with Digital Health Acquisition Corp., DHAC Merger Sub I, Inc., DHAC Merger Sub II, Inc., VSee Lab, Inc., and iDoc Virtual Telehealth Solutions, Inc. (effective 2022-11-03).
- Action
- amendment
- Agreement
- merger
- Counterparty
- Digital Health Acquisition Corp., DHAC Merger Sub I, Inc., DHAC Merger Sub II, Inc., VSee Lab, Inc., and iDoc Virtual Telehealth Solutions, Inc.
- Effective
- 2022-11-03
Exact text from the filing
On November 3, 2022, the parties to the Business Combination Agreement entered into the First Amendment to Second Amended and Restated Business Combination Agreement (the “First Amendment”), pursuant to which the Business Combination Agreement was amended to, among other things, delete a condition precedent to the consummation of the transactions contemplated by the Business Combination Agreement that the aggregate cash proceeds available after the completion of the transactions equal or exceed the amount of $10,000,000.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
VSEE HEALTH, INC. entered into Securities Purchase Agreement (the "Purchase Agreement") with A.G.P./Alliance Global Partners (the "Representative") (effective 2022-11-03).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- A.G.P./Alliance Global Partners (the "Representative")
- Effective
- 2022-11-03
Exact text from the filing
On November 3, 2022, the Company and A.G.P./Alliance Global Partners (the “Representative”) entered into a Securities Purchase Agreement (the “Purchase Agreement”), pursuant to which the Company will issue 4,370 shares (the “Series B Shares”) of its Series B Convertible Preferred Stock, par value $0.0001 per share (the “Series B Preferred Stock”), at a per share price of $1,000 to the Representative upon the closing of the transactions contemplated by the Business Combination Agreement in full satisfaction of the Representative’s $4,370,000 deferred underwriting fee payable by the Company to the Representative pursuant to the Underwriting Agreement, dated November 3, 2021, between the Company and the Representative.
View on SEC.gov